Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
Alzheimer's & Dementia · 2024-05 · 20 (5) · 3251-3269
DOI: 10.1002/alz.13789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 19.03.2024. Verfasst von Shu-Yi Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Fronti…. Hauptthemen laut MEDLINE: Alzheimer Disease, Disease Progression, Glymphatic System, Positron-Emission Tomography. Die Arbeit wurde bisher 302-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Rising-Star Program, Shanghai Talent Development Funding for The Project, Tianqiao and Chrissy Chen Institute.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Although glymphatic function is involved in Alzheimer's disease (AD), its potential for predicting the pathological and clinical progression of AD and its sequential association with core AD biomarkers is poorly understood. METHODS Whole‐brain glymphatic activity was measured by diffusion tensor image analysis along the perivascular space (DTI‐ALPS) in participants with AD dementia ( n = 47), mild cognitive impairment (MCI; n = 137), and normal controls ( n = 235) from the Alzheimer's Disease Neuroimaging Initiative. RESULTS ALPS index was significantly lower in AD dementia than in MCI or controls. Lower ALPS index was significantly associated with faster changes in amyloid positron emission tomography (PET) burden and AD signature region of interest volume, higher risk of amyloid‐positive transition and clinical progression, and faster rates of amyloid‐ and neurodegeneration‐related cognitive decline. Furthermore, the associations of the ALPS index with cognitive decline were fully mediated by amyloid PET and brain atrophy. DISCUSSION Glymphatic failure may precede amyloid pathology, and predicts amyloid deposition, neurodegeneration, and clinical progression in AD. Highlights The analysis along the perivascular space (ALPS) index is reduced in patients with Alzheimer's disease (AD) dementia, prodromal AD, and preclinical AD. Lower ALPS index predicted accelerated amyloid beta (Aβ) positron emission tomography (PET) burden and Aβ‐positive transition. The decrease in the ALPS index occurs before cerebrospinal fluid Aβ42 reaches the positive threshold. ALPS index predicted brain atrophy, clinical progression, and cognitive decline. Aβ PET and brain atrophy mediated the link of ALPS index with cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan Universi…
- Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, School of Clinical Medicine, UNSW, Sydney, New South Wales, Australia.
- Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.
- Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry of Education, Shanghai, China.
- Fudan ISTBI-ZJNU Algorithm Centre for Brain-Inspired Intelligence, Zhejiang Normal University, Jinhua, China.
- Shanghai Medical College and Zhongshan Hospital Immunotherapy Technology Transfer Center, Fudan University, Shanghai, China.
Förderung
- Shanghai Rising-Star Program
- Shanghai Talent Development Funding for The Project
- Tianqiao and Chrissy Chen Institute
- Research Start-up Fund of Huashan Hospital
- State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Major Project
- Excellence 2025 Talent Cultivation Program at Fudan University
Zitieren
APA
Huang, S. Y., Zhang, Y. R., Guo, Y., Du, J., Ren, P., Wu, B. S., Feng, J. F., Alzheimer's Disease Neuroimaging Initiative, Cheng, W., & Yu, J. T. (2024). Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease. Alzheimer's & Dementia, 20(5), 3251-3269. https://doi.org/10.1002/alz.13789
Vancouver
Huang SY, Zhang YR, Guo Y, Du J, Ren P, Wu BS, et al. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease. Alzheimer's & Dementia. 2024;20(5):3251-3269. doi:10.1002/alz.13789
BibTeX
@article{Huang2024,
author = {Huang, Shu-Yi and Zhang, Ya-Ru and Guo, Yu and Du, Jing and Ren, Peng and Wu, Bang-Sheng and Feng, Jian-Feng and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Cheng, Wei and Yu, Jin-Tai},
title = {Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {5},
pages = {3251--3269},
doi = {10.1002/alz.13789}
}
EUVIMED